Advanced Breast Cancer Clinical Trials in San Antonio, Texas
13 recruitingSan Antonio, Texas
Showing 1–13 of 13 trials
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled150 locationsNCT07085767
Recruiting
Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled42 locationsNCT06638307
Recruiting
Phase 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled298 locationsNCT06380751
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled41 locationsNCT06827236
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Triple-Negative Breast CancerColorectal, CancerAdvanced Breast Cancer+2 more
Pfizer260 enrolled9 locationsNCT07318805
Recruiting
Phase 1Phase 2
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled15 locationsNCT06993844
Recruiting
Phase 1Phase 2
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
HR+/HER2- Advanced Breast CancerHR+/HER2- Breast Cancer
Avenzo Therapeutics, Inc.380 enrolled14 locationsNCT06998407
Recruiting
Phase 1
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer
Bristol-Myers Squibb234 enrolled21 locationsNCT06997029
Recruiting
Phase 1
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer
Boundless Bio, Inc.96 enrolled8 locationsNCT07408089
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 1Phase 2
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
HR+/HER2- Advanced Breast CancerTriple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613